Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of RO7821657 in Participants With Solid Tumors

13. november 2026 opdateret af: Hoffmann-La Roche

A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors

The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])

The study consists of two parts, namely Part 1 and Part 2:

Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).

Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

405

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Undersøgelse Kontakt Backup

Studiesteder

      • København Ø, Danmark, 2100
        • Rekruttering
        • Rigshospitalet
      • Sutton, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • Royal Marsden Sutton

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Life expectancy estimated by the Investigator to be ≥12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
  • Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
  • Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
  • Adequate cardiovascular function:

New York Heart Association (NYHA) Heart Failure Class ≤ 1.

  • Agreement to adhere to the contraception requirements.

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) metastases.

  • Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.

    a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.

  • History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.

  • Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.

  • Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1A: Dose Escalation

Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Eksperimentel: Part 1B: Backfill Cohorts

Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A.

Participants will receive RO7821657 as per the schedule described in the protocol.

Eksperimentel: Part 1C: Dose Expansion/Optimization

Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B.

Participants will receive RO7821657 as per the schedule described in the protocol.

Eksperimentel: Part 2A: Abbreviated Dose Escalation

Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Eksperimentel: Part 2B: Dose Expansion/Optimization

Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A.

Participants will receive RO7821657 as per the schedule described in the protocol.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1: Incidence and Severity of Adverse Events (AEs)
Tidsramme: Up to approximately 27 months

AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria

Up to approximately 27 months
Part 2: Incidence and Severity of Adverse Events (AEs)
Tidsramme: Up to approximately 27 months

AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria

Up to approximately 27 months
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
Tidsramme: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Part 2A: Nature and Frequency of DLTs
Tidsramme: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Part 2A: RP2D Range of RO7821657
Tidsramme: Up to approximately 27 months
Up to approximately 27 months

Sekundære resultatmål

Resultatmål
Tidsramme
Parts 1 and 2: Serum Concentration of RO7821657
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Objective Response Rate (ORR)
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Disease Control Rate (DCR)
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Duration of Response (DoR)
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Progression-free Survival (PFS)
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: PFS Rate
Tidsramme: At 6 months
At 6 months
Parts 1 and 2: Overall Survival (OS) Rate
Tidsramme: At 6 months
At 6 months
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
Tidsramme: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
Tidsramme: Up to approximately 27 months
Up to approximately 27 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Trials, Hoffmann-La Roche

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. november 2026

Primær færdiggørelse (Anslået)

31. maj 2030

Studieafslutning (Anslået)

31. maj 2030

Datoer for studieregistrering

Først indsendt

14. oktober 2026

Først indsendt, der opfyldte QC-kriterier

14. oktober 2026

Først opslået (Faktiske)

20. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • BP46447
  • 2026-526150-14-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .